314 results about "Poor prognosis" patented technology

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

This invention relates, e.g., to a method for predicting the response of a subject having estrogen-receptor-positive breast cancer to an inhibitor of the estrogen signaling pathway (e.g. tamoxifen), comprising measuring in a cancer sample from the subject the level of phosphorylation, compared to a baseline value, of one or more of the following members of an interconnected intracellular signaling pathway: (a) 4EBP1, and/or (b) p70S6, and/or (c) STAT3, and/or (d) FAK, wherein a significantly elevated level of phosphorylation of 4EBP1, and/or p70S6 and/or STAT3, and/or a significantly decreased level of phosphorylation of FAK, compared to the baseline value, indicates that the subject is likely to be a non-responder to the inhibitor and/or has a poor prognosis. Additional members of the intracellular signaling pathway whose phosphorylation can be measured are also described. Also described is a method for treating breast cancer in a subject in need thereof, wherein the subject exhibits an elevated level of phosphorylation of these markers, comprising administering to the subject an effective amount of one or more inhibitors of members of the interconnected intracellular signaling pathway.

The invention provides a variety of reagents for use in the diagnosis and management of cancer, particularly breast cancer. cDNA microarray technology was used to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5 and cytokeratin 17, markers for basal cells of the normal mammary lactation gland. The invention demonstrates that tumors that express cytokeratin 5/6 and/or 17 have a poor prognosis relative to tumors overall. The invention provides basal marker genes and their expression products and uses of these genes for diagnosis of cancer and for identification of therapies for cancer. In particular, the invention provides basal marker genes including cadherin3, matrix metalloproteinase 14, and cadherin EGF LAG seven-pass G-type receptor 2. The invention provides antibodies to the polypeptides expressed by these genes and methods of use thereof.

The method of the present invention is used to select high risk or co-morbid patients for participation in a care management program. An acuity score determines which patients are selected for care management.

This invention relates, e.g., to a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation compared to a positive and/or negative reference standard, of one or more of: (a) AKT (S473); (b) BAD (S112); (c) cABL (T735); (d) ERK (T42/44); (e) MARCKS (S152-156); (0 p38MAPK (T180-182): (g) STAT 1 (Y701 ); (h) PTEN (S380); (i) EGFR (Y992); (j) PAK 1/2 (S 1 19/204); or (k) PKC zeta/lambda (T410-403); or the total amount of (1) COX-2 protein; wherein if the level of phosphorylation of one or more of a-i or the total amount of COX-2 protein (1) is elevated compared to the negative reference standard, and/or if the level of phosphorylation of j or k is decreased compared to the positive reference standard, the subject has poor prognosis, is likely to undergo metastasis, and/or is a good candidate for aggressive therapy. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing methods of the invention.

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.

The invention discloses a sepsis early diagnosis liquid chip which mainly includes the following components: microsphere coated with PCT capturing antibody, microsphere coated with CRP capturing antibody, microsphere coated with IL-6 capturing antibody, microsphere coated with Neopterin capturing antibody, these microspheres have codes with different colors; biotin-labeled test antibody; avidin-linked phycoerythrin. The invention sepsis early diagnosis liquid chip has advantages of high detection efficiency, a small amount of sample, high specificity and high sensitivity. And at the same time, the invention can test four kinds of specific markers of sepsis simultaneously, improve sensitivity and specificity of sepsis early diagnosis, distinguish sepsis caused by bacterial and viral, judge severity and poor prognosis of sepsis and monitor continuously for judging reflection of patient to certain kind of treatment.

The present invention is directed to the full-length cDNA sequence encoding human diaphanous-3 (DIAPH3), to DIAPH3 encoded thereby, and to fragments of DIAPH3 and the cDNA. The present invention also provides for the use of the cDNA, and of DIAPH3, as a marker of poor prognosis of breast cancer. Because DIAPH3 appears essential for proper spindle pole formation during mitosis, DIAPH3 is a useful target for screening assays designed to identify inhibitors or modulators of DIAPH3 activity, which are useful for the treatment of cancer, particularly breast cancer. Thus, the invention further provides methods of using DIAPH3, or fragments thereof, in assays to identify such compounds.

The present invention relates to methods and kits for detecting several polynucleotide sequence found to be indicative of a poor prognosis of B-CLL. All the polynucleotides are transcribed from a region on human chromosome 12p21-22. Most of the polynucleotides do not encode larger polypeptides, but may encode small peptides, they may function as RNAs. Four polynucleotides encode a novel protein, which in one preferred embodiment can be used as a cytokine, preferably as an interleulkin. Furthermore the invention relates to methods and compositions for treating B-CLL in particular poor prognosis B-CLL.

The invention relates to the technical field of medical molecular biology and provides a method for detecting the serum marker of pancreatic cancer. The pancreatic cancer has high grade malignancy, difficult early diagnosis and poor prognosis, and the pancreatic cancer also lacks really effective solution, with surgical resection as the only therapeutic method to prolong survival period. Unfortunately, most of pancreatic cancer patients are in the advanced stage (TNM belongs to III and IV stages) and miss the surgical option. The invention aims at providing a method for detecting the serum marker of pancreatic cancer and applying the method to early diagnosis of pancreatic cancer and clinical judgment of laparotomy indication. The study proves that in the invention, the expression level of miR-196a in the serum is closely related to the postoperative survival period of pancreatic cancer; the study later proves that the relative expression abundance of miR-196a can well distinguish resectable pancreatic cancer (TNM belongs to I and II stages) from pancreatic cancer in advanced stage (TNM belongs to III and IV stages), so the method in the invention can be used for detecting the serum marker microRNA-196a of pancreatic cancer, and the method further has the advantages of convenient detection, good sensitivity and high accuracy.

The present invention includes methods for treating a FLT3 mutated proliferative disorder comprising: measuring expression of a mutated FLT3 and one or more genetic abnormalities in a sample obtained from a tumor sample obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, wherein the crenolanib increases a chance of survival of the patient having both the mutated FLT3 and the one or more genetic abnormalities, wherein the crenolanib, as shown below, is administered to a subject suffering from said disorder:

The invention relates to a diagnostic marker for malignant glioma and belongs to the technical field of molecular biology. Particularly, the marker is an NES gene and an expression product thereof. The diagnostic marker has the advantages that comprehensive genomics and proteomics analysis is carried out on a GBM, and through gene expression analysis based on a gene chip and RNA sequencing and proteome analysis of LC/MS/MS, the mRNA level and protein level of the NES gene are regulated up. Through survival analysis on the NES, over-expression of the NES is related to poor prognosis of a GBM patient, so that the NES can be used as a GBM biomarker and a potential therapeutic target. The NES gene is used for encoding nestin protein, is mainly applied to nerve cell expression, and can be used as the GBM biomarker and the potential therapeutic target.

The invention belongs to the field of genetic engineering and in particular relates to an application of a bile exosome long and non-coding RNA (lncRNA) ENST00000588480.1 in diagnosis of bile duct carcinoma, prognostic prediction and target spot drug treatment, wherein the long and non-coding RNA is positively correlated with TNM staging and poor prognosis of a patient.

This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.

Cellular markers indicating a poor prognosis for ovarian cancer patients are disclosed. In particular, the invention relates to methods utilizing the frequency of a subset of cells in ovarian tumor tissue expressing vimentin, cMyc, or HE4, or any combination thereof, to predict an ovarian cancer patient will relapse.

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.

The invention discloses an LncRNA composition for detecting prognosis of an early esophageal cancer and a kit comprising the LncRNA composition. By fluorescent quantitative PCR, a sample (which can be tissues/plasma serum and the like) of a patient with an esophageal cancer and difference change of the expression amount of a group of LncRNA in a corresponding para-carcinoma tissue/reference sample are identified, and the risk of esophageal cancerrelapse or transfer is accurately evaluated early. The kit can be used for accurately detecting early esophageal cancer transfer potential, then the transfer or relapse risk of a postoperative esophageal cancer patient can be accurately predicted and evaluated, the patient with high risk is intensively monitored and intervened effectively, relapse or transfer of the esophageal cancer is reduced, and prognosis of the patient is improved further. The poor prognosis related lncRNA composition is adopted, and the shortcomings that sensitivity and specificity are low due to the fact that a kit only uses single lncRNA as a tumor marker, and therefore, rate of fault diagnosis and rate of missed diagnosis on the esophageal cancer are greatly increased are overcome.

The invention belongs to the technical field of genetic engineering, and discloses long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs. Cancers include colorectal cancer, breast cancer, kidney cancer and the like. Expression of the long noncoding RNA SNHG15 in tumor tissues of patients suffering from the colorectal cancer, the breast cancer andthe kidney cancer is up-regulated. The patients with highly-expressed long noncoding RNA SNHG15 have poor prognosis. Through expression knock-down of the long noncoding RNA SNHG15 in colorectal cancercell lines, invasion, migration and multiplication capabilities of cells can be inhibited, and drug susceptibility of colorectal cancer cell lines to antitumor drugs including gemcitabine and cis-platinum can be improved.

The invention discloses a molecular marker associated with colorectal carcinoma metastasis and prognosis as well as application of the molecular marker. The molecular marker is a ribosomal protein analog RPL22L1 (Ribosomal protein L22-like 1). A research proves that the ribosomal protein analog RPL22L1 is associated with occurrence and development of tumors, expression levels of the ribosomal protein analog in clinical colorectal carcinoma tissues rise, the expression levels of the ribosomal protein analog are obviously associated with metastasis occurrence and poor prognosis, and the colorectal carcinoma metastasis can be promoted by multiple regulation pathways. According to the molecular marker associated with colorectal carcinoma metastasis and prognosis disclosed by the invention, by detecting the expression levels of RPL22L1 genes in the colorectal carcinoma, the RPL22L1 as a tumor molecular diagnosis marker is applied to clinical diagnosis of the colorectal carcinoma metastasis and prognosis evaluation, so that a new molecular marker is provided for early diagnosis on the colorectal carcinoma metastasis and prognosis evaluation of colorectal carcinoma patients.